In line with previous reports [11,13,25], our results support the potential use of liquid biopsy to monitor the response to treatment together with radiological and/or clinical assessment in locally advanced or metastatic melanoma patients with a BRAF-V600/NRAS mutation already identified by baseline liquid biopsy. This evidence concerns the gene BRAF and metastatic melanoma.